Arvee Laboratories (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
ARVEE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Arvee Laboratories submitted its unaudited financial results for the quarter and nine months ended December 31, 2025. Q3 FY26 revenue from operations rose to ₹977.95 lakhs from ₹890.85 lakhs in Q3 FY25, a ~10% year-on-year increase, while profit after tax jumped to ₹182.69 lakhs from ₹15.48 lakhs (largely aided by a ₹66.09 lakh deferred tax credit). However, on a nine-month basis, revenue fell sharply to ₹2,071 lakhs from ₹3,203.72 lakhs in 9M FY25, a decline of roughly 35%. 9M profit before tax dropped to ₹157.68 lakhs from ₹277.72 lakhs, though PAT was nearly flat at ₹200.61 lakhs vs ₹207.82 lakhs due to tax adjustments. EPS for Q3 was ₹1.66 and for 9M FY26 was ₹1.82. Auditor Nirav Patel & Associates issued an unqualified limited review report.
The sharp 35% drop in nine-month revenue is a red flag for shareholders, signalling sustained weakness in the chemicals business despite a stronger Q3. Margin pressure on a year-to-date basis suggests the company is operating in a challenging environment, though the quarterly recovery in profitability may ease near-term concerns.